Table 5.
Current Anti-IGF treatment of sarcomas.
| Monoclonal antibodies | Human trials | Disease control rate (CR, PR, and SD) | Comments |
|---|---|---|---|
| Figitumumab CP-751, 871 | ES/STS | 10/28 (35%) | Anti-IGF-IR |
| Cixutumumab | STS | 22/37 (59%) | Liposarcomas; block hybrid receptors |
| Robatumumab SCH 717454 | Preclinical | OS, RMS | Anti-IGF-IR |
| Ganitumab AMG479 | ES | 2/15 (13%) | |
| RI 507 | ES | 18/125 (14.4%) | No SD included |
|
| |||
| TK inhibitors | Status | Target disease | |
|
| |||
| NVP-AEW541 | Preclinical | ES/STS/GIST | Synergy with chemoRx |
| NVP-ADW 742 | Preclinical | ES | Synergy with imatinib |
| BMS-536924 | Preclinical | STS | ATP-competitive IGF-IR |
|
| |||
| Others | Status | Target disease | |
|
| |||
| Nordihydroguaiaretic acid (NDGA) | Preclinical | STS | Disrupts IGF-1R; blocks HER-2 |